Baker Bros. Advisors RLAY Position
Active14-Fund ConvergenceBaker Bros. Advisors held their position in Relay Therapeutics Inc. (RLAY) in Q4 2025, holding $9.8M worth of shares across 1,160,117 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
RLAY is a convergence signal: 14 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for RLY-2608 in 747 days (Apr 30, 2028), making the timing of Baker Bros.'s position particularly relevant.
Short interest stands at 13.4% of float with 7.6 days to cover, indicating significant bearish positioning against Baker Bros.'s long thesis.
About Relay Therapeutics Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Full company profile →Short Interest
13.4%
7.6 days to cover
Baker Bros. Advisors RLAY Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 1,160,117 | — | $9.8M |
| Q3 2025 | Held | 1,160,117 | — | $6.1M |
| Q2 2025 | Held | 1,160,117 | — | $4.0M |
| Q1 2025 | Held | 1,160,117 | — | $3.0M |
| Q4 2024 | Held | 1,160,117 | — | $4.8M |
| Q3 2024 | Held | 1,160,117 | — | $8.2M |
| Q2 2024 | Held | 1,160,117 | — | $7.6M |
| Q1 2024 | Held | 1,160,117 | — | $9.6M |
| Q4 2023 | Held | 1,160,117 | — | $12.8M |
| Q3 2023 | Held | 1,160,117 | — | $9.8M |
| Q2 2023 | Increased | 1,160,117 | +876,117 | $14.6M |
| Q1 2023 | New | 284,000 | +284,000 | $4.7M |
Frequently Asked Questions
Does Baker Bros. Advisors own RLAY?
Yes. As of Q4 2025, Baker Bros. Advisors holds 1,160,117 shares of Relay Therapeutics Inc. (RLAY) valued at $9.8M. This data comes from their SEC 13F filing.
How many hedge funds own RLAY?
14 specialist biotech hedge funds currently hold RLAY, including Foresite Capital, Commodore Capital, Casdin Capital and 10 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Baker Bros. Advisors first buy RLAY?
Baker Bros. Advisors's position in RLAY was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Baker Bros. Advisors's RLAY position increasing or decreasing?
Baker Bros. Advisors held their RLAY position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
RLAYCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Baker Bros. AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →